- Home
- RYI vs AUTL Comparison
RYI vs AUTL Comparison
Compare RYI & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RYI | AUTL |
|---|---|---|
| Founded | 1842 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 822.6M | 433.8M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | RYI | AUTL |
|---|---|---|
| Price | $25.98 | $1.75 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $25.00 | $8.33 |
| AVG Volume (30 Days) | 374.9K | ★ 4.0M |
| Earning Date | 10-28-2025 | 11-12-2025 |
| Dividend Yield | ★ 2.87% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,473,900,000.00 | $51,128,000.00 |
| Revenue This Year | $0.38 | $658.11 |
| Revenue Next Year | $4.72 | $91.34 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 406.67 |
| 52 Week Low | $17.18 | $1.11 |
| 52 Week High | $27.41 | $2.80 |
Technical Indicators
Market Signals| Indicator | RYI | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 66.31 | 64.58 |
| Support Level | $23.57 | $1.56 |
| Resistance Level | $26.39 | $1.69 |
| Average True Range (ATR) | 1.02 | 0.10 |
| MACD | 0.19 | 0.02 |
| Stochastic Oscillator | 80.82 | 86.96 |
Price Performance
Historical ComparisonAbout RYI Ryerson Holding Corporation
Ryerson Holding Corp provides a metals service center, and value-added processor and is a distributor of industrial metals with operations in the United States, Canada, and Mexico. In addition to its North American operations, it conducts processing and distribution operations in China. Its customers range from local, independently owned fabricators and machine shops to large, international original equipment manufacturers. It carries a full line of products in stainless steel, aluminum, carbon steel, and alloy steels and a limited line of nickel and red metals in various shapes and forms. The company generates substantially all of its revenue from sales of metal products. Geographically, the majority revenue is generated from the United States.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.